

EQA round: BIL2/24 - Bilirubin Neonatal

Deadline: 23.8.2024

Setup: groups - M (measurement principle); Slovakia; minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D _{max} = acceptable difference
SD = standard deviation	CVP = consensus of all participants	LL = lower limit
CV = coefficient of variation	CVPG = consensus of the participants' groups	UL = upper limit
N _{tot} = total number of the results	U _{AV} = expanded uncertainty of the assigned value (k = 2)	N _{eva} = number of the results assessed
N _{out} = number of the results removed before calculation		N _{suc} = number of successful results
		S _{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability						N _{eva}	N _{suc}	S _{rel} [%]
							AV	U _{AV}	D _{max}	LL	UL				
(215) Bilirubin total	[μmol/L]				18								18	18	100
Sample A		322	16	4,8	18		CVP	322	5,6	18%	264	380	18	18	100
(2) DCA, DPD		319	15	4,8	14	0							14		
Other					4	0							4		
							2x 1, 1x 5, 1x 7								
Sample B		206	9,3	4,5	18		CVP	205	3,7	18%	168	242	18	18	100
(2) DCA, DPD		204	9,6	4,7	14	0							14		
Other					4	0							4		
							2x 1, 1x 5, 1x 7								
(216) Bilirubin direct	[μmol/L]				15								15	14	93
Sample A		63,1	7,7	12	15								15	14	93
(2) DCA, DPD; (58) Beckman Coulter (AU)		66,5	4,3	6,5	11	0	CVPG	67,4	2,3	18%	55,2	79,6	11		
Other					4	0							4		
							1x 2/1, 2x 2/60, 1x 7/179								
Sample B		45,2	7,3	16	15								15	15	100
(2) DCA, DPD; (58) Beckman Coulter (AU)		48,5	3,6	7,5	11	0	CVPG	48,7	1,6	18%	39,9	57,5	11		
Other					4	0							4		
							1x 2/1, 2x 2/60, 1x 7/179								